Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Elevance Health to $561 from $597 and keeps an Overweight rating on the shares. While EPS was modestly better-than-expected, lack of core MLR favorability coupled with declining DCP was viewed negatively, particularly given Commercial and Med Adv margin improvement targets. Focus will remain on cost trend and MLR trajectory, Wells says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ELV:
- Elevance Health price target lowered to $550 from $565 at Loop Capital
- Elevance Health initiated with an Overweight at Cantor Fitzgerald
- Elevance Health price target raised to $575 from $571 at Deutsche Bank
- Elevance Health price target lowered to $564 from $577 at TD Cowen
- Elevance Health reports Medical enrollment of 48.1M members on March 31